In 2018, there was an outbreak of synthetic cannabinoid-associated coagulopathy due to contamination of synthetic cannabinoids with broudifacoum, difenacoum and bromodialone. A recent study evaluated blood samples of 32 patients treated for bleeding disorders to this outbreak. What did this study find in regards to the half life of broudifacoum and the route of administration of Vitamin K1?
As expected, the half lives of broudifacoum and difacoum were ~7 days compared to bromodialone which was ~2 days. Interestingly, the half life of broudifacoum was shorter in patients receiving intravenous vitamin K1 compared to oral vitamin K1. (Feinstein DL et al. Effects of vitamin K 1 treatment on plasma concentrations of long acting anticoagulant rodenticide enantiomers following inhalation of contaminated synthetic cannabinoids. Clin Tox 2020; 58(7): 716-724)